Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG

Trial Profile

A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dacomitinib (Primary)
  • Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Jan 2021 Data (n=266) pooled from two studies (Study 1017 and ARCHER 1050) were used for longitudinal tumor growth inhibition model to evaluate the effectiveness of the dacomitinib dosing regimen methods, presented at the 2020 World Conference on Lung Cancer.
    • 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 19 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top